Skip to content
Health News

Covid-19: India red list add ‘may be too late’, Prof Mark Walport says

By health | April 20, 2021
0 Comment

[unable to retrieve full-text content]There are “good reasons” for keeping the new variant out of the UK, scientist Prof Mark Walport says.
BBC News – Health

Category: Advertising & Marketing Tags: *may*, COVID19, India, Late., List, Mark, Prof, Says, Walport
Post navigation
← CPSC Warns Against Using Peloton Treadmill After Child’s Death U.S. FDA Approves ALK’s Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis →
  • Is barley ok for keto diet

    There are pros and cons to each of these additives. How do you get raw full fat dairy? They are made from cracked parboiled groats of several wheat species, most often from durum wheat. Hi Lisa, I’m not sure I understand your question. Why, because if they would show how the animals are slaughtered it… Read More »

  • Post-election health report: a time for healing

    We welcome comments, which users can leave at the end of any of our systematic story reviews or at the end of any of our blog posts. But before leaving a comment, please review these notes about our policy. You are responsible for any comments you leave on this site. This site is primarily a… Read More »

  • Junk Food ‘Brainwashes’ You so You’re Wired to Eat More

    If you’re like most people, you’re consuming an unhealthy amount of sugar on a regular basis. Even if you don’t consistently eat junk food, candy or sweetened beverages, most processed foods contain an excessive amount of added sugar. The BBC documentary1 “The Truth About Sugar,” revealed one serving of Pad Thai noodles has nearly 9.5… Read More »

  • FDA Approves Kimyrsa (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

    FDA Approves Kimyrsa (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) — Melinta Therapeutics, LLC (Melinta), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that the U.S. Food and Drug Administration (FDA) has approved… Read More »

Copyright 2017
Iconic One Theme | Powered by Wordpress